Opinion|Videos|January 15, 2025
Polycythemia Vera: Treatment Options
Author(s)Julie Huynh-Lu, P.A.
panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection based on individual risk factors and symptoms, while patients can actively participate in their care through lifestyle modifications and regular monitoring of blood counts, symptoms and cardiovascular risk factors to achieve both immediate symptom relief and long-term disease control.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly review the currently available treatment options for PV. How do they work? And how do you choose the right treatment?
- Is there a treatment for PV overall, or are there just treatments for individual symptoms?
- What are the short- and long-term goals for PV?
- How can patients be involved in managing their PV?
- How do you assess treatment response and monitoring of patients with PV?
Advertisement
Related to this article
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
Urologic Oncologist Answers Top Searched Questions in Bladder Cancer
4
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
5